西洛他唑在介入心脏病学中的潜力。

Current interventional cardiology reports Pub Date : 2000-05-01

Tsuchikane, Kobayashi, Awata

{"title":"西洛他唑在介入心脏病学中的潜力。","authors":"Tsuchikane, Kobayashi, Awata","doi":"","DOIUrl":null,"url":null,"abstract":"Cilostazol, an antiplatelet agent developed in Japan, has been demonstrated to have the potential to reduce restenosis after percutaneous transluminal coronary angioplasty (PTCA). Unlike conventional antiplatelet agents, cilostazol has several favorable properties in reducing restenosis. Besides the vasodilatory effect, cilostazol directly inhibits smooth muscle proliferation and may enhance reendothelialization after PTCA. Although the magnitude of prevention of restenosis may differ with the PTCA device used, cilostazol appears quite promising as a pharmacologic treatment adjunct to PTCA.","PeriodicalId":80270,"journal":{"name":"Current interventional cardiology reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2000-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Potential of Cilostazol in Interventional Cardiology.\",\"authors\":\"Tsuchikane, Kobayashi, Awata\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cilostazol, an antiplatelet agent developed in Japan, has been demonstrated to have the potential to reduce restenosis after percutaneous transluminal coronary angioplasty (PTCA). Unlike conventional antiplatelet agents, cilostazol has several favorable properties in reducing restenosis. Besides the vasodilatory effect, cilostazol directly inhibits smooth muscle proliferation and may enhance reendothelialization after PTCA. Although the magnitude of prevention of restenosis may differ with the PTCA device used, cilostazol appears quite promising as a pharmacologic treatment adjunct to PTCA.\",\"PeriodicalId\":80270,\"journal\":{\"name\":\"Current interventional cardiology reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current interventional cardiology reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current interventional cardiology reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

西洛他唑是日本开发的一种抗血小板药物，已被证明具有减少经皮腔内冠状动脉成形术(PTCA)后再狭窄的潜力。与传统的抗血小板药物不同，西洛他唑在减少再狭窄方面有几个有利的特性。除了血管舒张作用外，西洛他唑还能直接抑制平滑肌增殖，并可能增强PTCA后的再内皮化。虽然预防再狭窄的程度可能因使用PTCA装置而异，但西洛他唑作为PTCA辅助药物治疗似乎很有希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The Potential of Cilostazol in Interventional Cardiology.

Cilostazol, an antiplatelet agent developed in Japan, has been demonstrated to have the potential to reduce restenosis after percutaneous transluminal coronary angioplasty (PTCA). Unlike conventional antiplatelet agents, cilostazol has several favorable properties in reducing restenosis. Besides the vasodilatory effect, cilostazol directly inhibits smooth muscle proliferation and may enhance reendothelialization after PTCA. Although the magnitude of prevention of restenosis may differ with the PTCA device used, cilostazol appears quite promising as a pharmacologic treatment adjunct to PTCA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current interventional cardiology reports

自引率

0.00%

发文量

期刊最新文献

Infectious Agents, Antibiotics, and Coronary Artery Disease. Local Drug Delivery During Percutaneous Coronary Intervention. Historical Aspects of Transcatheter Closure of the Patent Ductus Arteriosus. Summary and Comparison of Atrial Septal Defect Closure Devices. Restenosis: Relationship with Thrombosis.